查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1434246

抗病毒药物市场：按药物、治疗方法和分销分类 - 全球预测 2023-2030

Antiviral Therapeutics Market by Drug (Hepatitis Antiviral Drug, Herpes Antiviral Drug, HIV Antiviral Drug), Therapy (DNA Polymerase Inhibitors, Neuraminidase Inhibitors, Protease Inhibitors), Distribution - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 199 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2022年抗病毒药物市场规模为695.4亿美元，2023年达755.3亿美元，预计2030年将达1,318.2亿美元，复合年增长率为8.32%。

全球抗病毒药物市场

主要市场统计
基准年[2022] 695.4亿美元
预计年份 [2023] 755.3亿美元
预测年份 [2030] 1318.2亿美元
复合年增长率（%） 8.32%
抗病毒药物-IMG1

抗病毒药物是专门设计用于透过针对病毒病原体并抑制其复製来减轻病毒性疾病的症状和传播的治疗方法。抗病毒药物用于各种医疗机构，从医院到专科诊所再到居家医疗。它们用于治疗多种病毒感染疾病，包括流感、肝炎、人类免疫力缺乏病毒 (HIV)、单纯疱疹病毒 (HSV) 以及最近的 SARS-CoV-2。由于世界各地各种慢性和病毒性疾病的盛行率不断增加，对抗病毒药物的需求正在扩大。药物研发活动的成长以及医疗保健成本的上升正在推动抗病毒药物市场的成长。与抗病毒药物相关的副作用增加了药物开发的成本并阻碍了抗病毒药物的成长。市场供应商扩大抗病毒药物研发活动预计将创造市场成长机会。

区域洞察

在美洲，由于大型製药公司的存在、先进的医疗基础设施以及病毒感染疾病的流行，抗病毒药物市场高度发展。公共和私营部门的大量投资推动了对创新治疗方法和研发 (R&D) 的关注。欧盟 (EU) 国家共同代表一个重要的市场，并由欧洲药品管理局 (EMA) 进行全面监管。高医疗保健标准和相对富裕的人口创造了消费者对最新治疗方案的强烈需求。许多欧盟国家普及全民健保，这意味着购买行为在很大程度上取决于监管部门的核准和国家医疗保健政策。中东和非洲 (MEA) 拥有多元化的市场，获得医疗保健的程度也各不相同。中东富裕国家拥有投资现代治疗方法的财政资源，但许多非洲国家在取得方面面临重大障碍。亚太地区正在迅速扩大其在抗病毒药物市场的影响力，其特点是对药物研发的投资增加以及需要医疗照护的人口基数不断增长。该地区本地製造业的不断增加和政府为改善医疗保健而采取的倡议正在推动亚太地区的市场成长。

FPNV定位矩阵

FPNV定位矩阵对于评估抗病毒药物至关重要。我们检视与商务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种详细的分析使用户能够根据自己的要求做出明智的决策。根据评级，供应商被分为四个不同的象限，代表不同的成功程度：前沿 (F)、探路者 (P)、利基 (N) 或重要 (V)。

市场占有率分析

市场占有率分析是一种综合工具，可以对抗病毒药物供应商的现状进行深入而详细的检查。仔细比较和分析供应商在整体收益、客户群和其他关键指标方面的贡献，帮助企业更好地了解其绩效以及在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵见解，包括在研究基准年期间观察到的累积、分散优势和合併特征等因素。这种扩展的详细程度使供应商能够做出更明智的决策并制定有效的策略，以获得市场竞争优势。

本报告在以下方面提供了宝贵的见解：

1-市场渗透率：显示主要企业提供的有关市场的全面资讯。

2- 市场发现：深入研究盈利的新兴市场并分析其在成熟细分市场的渗透率。

3- 市场多样性：提供有关新产品发布、未开发地区、最新发展和投资的详细资讯。

4- 竞争评估和情报：对主要企业的市场占有率、策略、产品、认证、监管核准、专利形势和製造能力进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的智慧见解。

该报告解决了以下关键问题：

1-抗病毒药物市场的市场规模和预测是多少？

2-在抗病毒药物市场的预测期内，我们应该考虑投资哪些产品、细分市场、应用和领域？

3-抗病毒药物市场的技术趋势和法律规范是什么？

4-抗病毒药物主要供应商的市场占有率是多少？

5-抗病毒药物进入领域合适的模式和策略性倡议是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 包括爱滋病毒和肝炎在内的病毒性疾病盛行率上升
      • 抗病毒药物在儿童及呼吸系统疾病的应用
      • 私人公司加大力度遏止病毒感染疾病
    • 抑制因素
      • 抗病毒药物治疗的费用相对较高
    • 机会
      • 加速药物发现的分子生物学进展
      • 改进病毒感染疾病的测试和分析
    • 任务
      • 抗病毒药物的副作用
  • 市场区隔分析
    • 药物：增加使用抗流感病毒药物来治疗和预防流感
    • 治疗方法：使用 DNA聚合酵素抑制剂来控制 HSV 和 VZV 的趋势不断增长
    • 分销：由于数位转型力度加大，线上药局的采用率增加
  • 市场趋势分析
  • COVID-19 的累积影响
  • 俄罗斯-乌克兰衝突的累积影响
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范
  • 客户客製化

第六章 抗病毒药物市场（按药物）

  • 肝炎抗病毒药
  • 疱疹抗病毒药物
  • 爱滋病毒抗病毒药物
  • 抗流感病毒药物

第七章 抗病毒药物市场：依治疗方法

  • DNA聚合酵素抑制剂
    • 非核苷类
    • 嘌呤核苷类似物
    • 嘧啶核苷类似物
  • 神经氨酸酶抑制剂
  • 蛋白酶抑制剂
  • 逆转录酶抑制剂
    • 非核苷类RTI
    • 核苷RTI
    • 核苷酸逆转录酶

第八章 抗病毒药物市场：依分布

  • 医院药房
  • 独立药房和药局
  • 网路药房

第九章美洲抗病毒药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区抗病毒药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲、中东和非洲抗病毒药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：按主要企业划分
  • 主要企业竞争情境分析
    • 合约、合作和伙伴关係
    • 新产品发布和功能增强
    • 奖项/奖励/扩展

第13章竞争产品组合

  • 主要公司简介
    • Abbott Laboratories
    • AbbVie Inc.
    • Alkem Laboratories Limited
    • AstraZeneca PLC
    • Atea Pharmaceuticals, Inc.
    • Aurobindo Pharma Limited
    • Bristol-Myers Squibb Company
    • Cipla Ltd.
    • Cocrystal Pharma, Inc.
    • Daiichi Sankyo Company, Ltd.
    • Dr. Reddy's Laboratories Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Gilead Sciences, Inc.
    • GlaxoSmithKline PLC
    • Hetero Labs Limited
    • Johnson & Johnson Services Inc.
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi SA
    • Sun Pharmaceutical Industries Limited
    • Syngene International Limited
    • Takeda Pharmaceutical Company Limited
    • Themis Medicare Ltd.
    • Venatorx Pharmaceuticals, Inc.
    • Viatris Inc.
    • Zydus Lifesciences Limited
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-037F3DB2592C

[199 Pages Report] The Antiviral Therapeutics Market size was estimated at USD 69.54 billion in 2022 and expected to reach USD 75.53 billion in 2023, at a CAGR 8.32% to reach USD 131.82 billion by 2030.

Global Antiviral Therapeutics Market

KEY MARKET STATISTICS
Base Year [2022] USD 69.54 billion
Estimated Year [2023] USD 75.53 billion
Forecast Year [2030] USD 131.82 billion
CAGR (%) 8.32%
Antiviral Therapeutics Market - IMG1

Antiviral therapeutics are therapeutics specifically designed to target viral pathogens and inhibit their replication, thereby alleviating the symptoms and spread of viral diseases. Antiviral drugs are used in various healthcare settings, ranging from hospitals to specialty clinics and home care. They are prescribed for the treatment of diverse viral infections, including influenza, hepatitis, Human Immunodeficiency Virus (HIV), Herpes Simplex Virus (HSV), and the recent SARS-CoV-2. The rising prevalence of various chronic and viral diseases worldwide is expanding the need for antiviral therapeutics. Growing pharmaceutical research and development activities with increasing healthcare expenditure are driving the growth of the antiviral therapeutics market. Side effects associated with antiviral drugs high cost of development of medication hampers the growth of antiviral therapeutics. Growing research and development activities to develop antiviral therapeutics by market vendors are expected to create opportunities for market growth.

Regional Insights

In the Americas, the antiviral therapeutics market is highly developing due to the presence of major pharmaceutical companies, advanced healthcare infrastructure, and a high prevalence of viral infections. Innovative treatment regimens and a strong focus on research & development (R&D) have been catalyzed by significant investment from both the public and private sectors. European Union (EU) countries collectively represent a significant market, with overarching regulations governed by the European Medicines Agency (EMA). High standards of healthcare and a relatively wealthy population translate to a strong consumer need for the latest therapeutic options. The prevalence of universal health coverage across many EU countries means that purchasing behavior is largely determined by regulatory endorsements and national health care policies. The Middle East and Africa (MEA) presents a diverse market with varying degrees of access to healthcare. Wealthier nations in the Middle East have the financial resources to invest in modern therapeutics, while many African countries face significant barriers to access. Asia-Pacific region is rapidly expanding its presence in the antiviral therapeutics market, marked by increasing investment in pharmaceutical R&D and a large population base requiring medical treatment. The growing availability of local manufacturing and government initiatives in the region to improve healthcare access is driving market growth in Asia-Pacific.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antiviral Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antiviral Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antiviral Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Alkem Laboratories Limited, AstraZeneca PLC, Atea Pharmaceuticals, Inc., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Cipla Ltd., Cocrystal Pharma, Inc., Daiichi Sankyo Company, Ltd., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline PLC, Hetero Labs Limited, Johnson & Johnson Services Inc., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Limited, Syngene International Limited, Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., Venatorx Pharmaceuticals, Inc., Viatris Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Antiviral Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Drug
    • Hepatitis Antiviral Drug
    • Herpes Antiviral Drug
    • HIV Antiviral Drug
    • Influenza Antiviral Drug
  • Therapy
    • DNA Polymerase Inhibitors
      • Non-nucleosides
      • Purine Nucleoside Analogues
      • Pyrimidine Nucleoside Analogues
    • Neuraminidase Inhibitors
    • Protease Inhibitors
    • Reverse Transcriptase Inhibitors
      • Nonnucleoside RTIs
      • Nucleoside RTIs
      • Nucleotide RTIs
  • Distribution
    • Hospital Pharmacy
    • Independent Pharmacy & Drug Store
    • Online Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antiviral Therapeutics Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antiviral Therapeutics Market?

3. What are the technology trends and regulatory frameworks in the Antiviral Therapeutics Market?

4. What is the market share of the leading vendors in the Antiviral Therapeutics Market?

5. Which modes and strategic moves are suitable for entering the Antiviral Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antiviral Therapeutics Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising Prevalence of Viral Diseases Including HIV and Hepatitis
      • 5.1.1.2. Application of Antiviral Therapeutics in Pediatric Care and Respiratory Diseases
      • 5.1.1.3. Increasing Initiatives to Curb Viral Diseases by Public and Private Companies
    • 5.1.2. Restraints
      • 5.1.2.1. Relatively High Cost Associated with Antiviral Drug Treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in Molecular Biology Promoting Drug Development
      • 5.1.3.2. Improved Testing and Analysis of Viral Infections
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse Effects of Antiviral Drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug: Growing usage of influenza antiviral drugs are used to treat and prevent influenza.
    • 5.2.2. Therapy: Rising inclination towards DNA polymerase inhibitors for the management of HSV and VZV
    • 5.2.3. Distribution: Growing adoption of online pharmacy with the rising digital transformation initiatives
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of COVID-19
  • 5.5. Cumulative Impact of Russia-Ukraine Conflict
  • 5.6. Cumulative Impact of High Inflation
  • 5.7. Porter's Five Forces Analysis
    • 5.7.1. Threat of New Entrants
    • 5.7.2. Threat of Substitutes
    • 5.7.3. Bargaining Power of Customers
    • 5.7.4. Bargaining Power of Suppliers
    • 5.7.5. Industry Rivalry
  • 5.8. Value Chain & Critical Path Analysis
  • 5.9. Regulatory Framework
  • 5.10. Client Customization

6. Antiviral Therapeutics Market, by Drug

  • 6.1. Introduction
  • 6.2. Hepatitis Antiviral Drug
  • 6.3. Herpes Antiviral Drug
  • 6.4. HIV Antiviral Drug
  • 6.5. Influenza Antiviral Drug

7. Antiviral Therapeutics Market, by Therapy

  • 7.1. Introduction
  • 7.2. DNA Polymerase Inhibitors
    • 7.3.1. Non-nucleosides
    • 7.3.2. Purine Nucleoside Analogues
    • 7.3.3. Pyrimidine Nucleoside Analogues
  • 7.3. Neuraminidase Inhibitors
  • 7.4. Protease Inhibitors
  • 7.5. Reverse Transcriptase Inhibitors
    • 7.6.1. Nonnucleoside RTIs
    • 7.6.2. Nucleoside RTIs
    • 7.6.3. Nucleotide RTIs

8. Antiviral Therapeutics Market, by Distribution

  • 8.1. Introduction
  • 8.2. Hospital Pharmacy
  • 8.3. Independent Pharmacy & Drug Store
  • 8.4. Online Pharmacy

9. Americas Antiviral Therapeutics Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antiviral Therapeutics Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antiviral Therapeutics Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. Agreement, Collaboration, & Partnership
      • 12.3.1.1. Gilead and Assembly Biosciences Establish Partnership to Develop Next-Generation Therapeutics for Serious Viral Diseases
    • 12.3.2. New Product Launch & Enhancement
      • 12.3.2.1. Shionogi Advances Ensitrelvir Fumaric Acid COVID-19 Antiviral Clinical Program
    • 12.3.3. Award, Recognition, & Expansion
      • 12.3.3.1. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AbbVie Inc.
    • 13.1.3. Alkem Laboratories Limited
    • 13.1.4. AstraZeneca PLC
    • 13.1.5. Atea Pharmaceuticals, Inc.
    • 13.1.6. Aurobindo Pharma Limited
    • 13.1.7. Bristol-Myers Squibb Company
    • 13.1.8. Cipla Ltd.
    • 13.1.9. Cocrystal Pharma, Inc.
    • 13.1.10. Daiichi Sankyo Company, Ltd.
    • 13.1.11. Dr. Reddy's Laboratories Ltd.
    • 13.1.12. Eli Lilly and Company
    • 13.1.13. F. Hoffmann-La Roche Ltd
    • 13.1.14. Gilead Sciences, Inc.
    • 13.1.15. GlaxoSmithKline PLC
    • 13.1.16. Hetero Labs Limited
    • 13.1.17. Johnson & Johnson Services Inc.
    • 13.1.18. Merck & Co., Inc.
    • 13.1.19. Novartis AG
    • 13.1.20. Pfizer Inc.
    • 13.1.21. Sanofi S.A.
    • 13.1.22. Sun Pharmaceutical Industries Limited
    • 13.1.23. Syngene International Limited
    • 13.1.24. Takeda Pharmaceutical Company Limited
    • 13.1.25. Themis Medicare Ltd.
    • 13.1.26. Venatorx Pharmaceuticals, Inc.
    • 13.1.27. Viatris Inc.
    • 13.1.28. Zydus Lifesciences Limited
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. ANTIVIRAL THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 5. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIVIRAL THERAPEUTICS MARKET DYNAMICS
  • FIGURE 7. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2022 VS 2030 (%)
  • FIGURE 8. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2022 VS 2030 (%)
  • FIGURE 10. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2030 (%)
  • FIGURE 12. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 22. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. ANTIVIRAL THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. ANTIVIRAL THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HEPATITIS ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HERPES ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HIV ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INFLUENZA ANTIVIRAL DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PURINE NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PYRIMIDINE NUCLEOSIDE ANALOGUES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NEURAMINIDASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 20. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NONNUCLEOSIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY NUCLEOTIDE RTIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 24. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY INDEPENDENT PHARMACY & DRUG STORE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. ANTIVIRAL THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 34. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 35. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 36. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 39. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 40. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 41. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 43. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 44. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 45. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 46. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 48. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 49. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 50. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 51. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 53. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 54. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 55. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 56. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 59. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 60. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 61. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 62. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 65. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 66. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 67. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 68. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 70. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 71. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 72. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 73. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 75. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 76. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 77. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 78. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 81. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 82. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 83. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 85. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 86. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 87. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 88. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 90. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 91. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 92. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 93. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 95. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 96. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 97. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 98. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 101. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 102. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 103. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 105. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 106. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 107. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 108. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 110. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 111. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 112. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 113. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 115. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 116. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 117. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 118. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 120. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 121. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 122. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 123. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 131. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 132. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 133. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 134. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 136. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 137. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 138. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 139. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 142. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 143. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 144. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 146. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 147. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 148. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 149. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 151. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 152. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 153. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 154. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 156. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 157. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 158. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 159. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 162. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 163. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 164. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 166. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 167. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 168. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 169. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 171. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 172. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 173. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 174. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 176. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 177. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 178. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 179. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 182. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 183. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 184. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 186. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 187. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 188. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 189. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 191. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 192. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 193. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 194. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 196. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 197. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 198. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 199. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 201. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 202. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 203. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 204. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 206. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 207. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 208. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 209. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 211. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 212. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 213. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 214. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 216. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 217. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 218. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 219. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 221. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 222. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 223. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 224. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 226. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 227. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 228. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 229. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DRUG, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY THERAPY, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DNA POLYMERASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY REVERSE TRANSCRIPTASE INHIBITORS, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM ANTIVIRAL THERAPEUTICS MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 236. ANTIVIRAL THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 237. ANTIVIRAL THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 238. ANTIVIRAL THERAPEUTICS MARKET LICENSE & PRICING